A Study of Dasatinib as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia (CML-CP)

Clinical trial NCT04925141 · COMPLETED

Trial details

NCT number

NCT04925141

Sponsor

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Status

COMPLETED

Phase

Phase 4

Study type

INTERVENTIONAL

Start date

2016-05-10

Primary completion

2018-10-22

Enrollment

62

View on ClinicalTrials.gov